E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale
Sandeep Gurram, Ruchi P. Patel, Andre R. Kydd, Elias Chandran et al.
Citations
1 citations
Journal
Future Oncology
Topics
Ovarian cancer diagnosis and treatment
Field-Weighted Citation Impact (FWCI)
1.70
article
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale
Sandeep Gurram, Ruchi P. Patel, Andre R. Kydd, Elias Chandran, Nicholas I. Simon, Andrea B. Apolo, Lisa M. Cordes, Seth M. Steinberg, Scot A. Niglio, Ian Stukes, Saad Atiq, Tzu-Fang Wang, Salah Boudjadi, Bernadette Redd, Dilara Akbulut, Daniel M. Girardi, Rouf Banday, Elizabeth Smith, Lisa Ley
article en
1 citations
Abstract
No abstract available for this paper.
Publication Tag
Future OncologyVol. 21(13)
Institutions
National Institutes of Health (US), NYU Langone Health (US), Office of the Director (US), Hinge Health (US), National Cancer Institute (US), Center for Cancer Research (US)
Ask Laika to Summarize, Analyze, and Connect papers live on the map.
Summarize Papers & Methodologies
Extract key findings, datasets, and comparative methods across publications.
Benchmark Rankings & Visual Analytics
Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.
Connect Distant Disciplines
Bridge topological clusters on the map to find hidden collaborative intersections.
E-VIRTUE: a study of enfortumab vedotin with or without pembrolizumab in rare genitourinary tumors—design and rationale — Sandeep Gurram, Ruchi P. Patel, et al. · Future Oncology (2025) | TGRS Research Map | TGRS